Exosome treatments have joined PRP and microneedling on hair-clinic menus, usually described as a regenerative "next step" for thinning hair. This page counts what has actually been published and registered. It does not recommend any product or procedure; hair loss has several causes, and a diagnosis from a dermatologist comes before any treatment choice.
What an exosome is, and why it is not a peptide
An exosome is a very small packet (roughly 30 to 150 nanometres across) that a cell releases, wrapped in its own membrane and carrying proteins, fats and genetic material such as microRNA. Laboratory work suggests these packets pass signals between cells. In hair research, the idea is that packets from stem cells or from the hair follicle's own dermal papilla cells could nudge follicles back into their growth phase.
An exosome is not a peptide. A peptide is a short chain of amino acids; an exosome is a whole membrane structure that may contain many proteins. This site covers exosomes because they are sold beside peptide hair serums and readers ask about them, just as our PDRN page covers a DNA fragment for the same reason.
The word also covers very different materials. The studies below used exosomes from fat-derived stem cells, from umbilical-cord stem cells, from foreskin-derived stromal cells, from hair-follicle cells and from plants. A plant-derived "exosome" and a human stem-cell exosome share a name, not a composition, so a result for one does not transfer to the other.
The literature, counted
On 28 September 2026, Europe PMC's copy of MEDLINE held 220 records mentioning exosomes or extracellular vesicles together with hair loss, alopecia or hair growth. The field is young and growing fast:
| Year | Records |
|---|---|
| 2019 | 6 |
| 2020 | 9 |
| 2021 | 13 |
| 2022 | 20 |
| 2023 | 12 |
| 2024 | 26 |
| 2025 | 65 |
| 2026 (to 28 Sept) | 65 |
Most of those records are laboratory, animal or review papers. The clinical subset is much smaller. A 2025 review in Dermatologic Surgery by Queen and Avram searched three databases and found nine clinical studies relevant to alopecia, in which 125 patients in total had received an exosome treatment (PMID 39447204). A 2023 systematic review by Gupta and colleagues had found 16 studies, of which 15 were preclinical and one was clinical (PMID 37381168).
The publication-type filter for randomized controlled trials returned no records at all for the same search, although one trial described as randomized does exist (below). We report that as a limit of the indexing, not as a finding about the trials.
The human studies
| Study | Who | What was given | What was reported |
|---|---|---|---|
| Park 2022 (PMID 35157363) | 39 people with hair loss, retrospective | Topical fat-derived stem-cell exosomes | Increases in hair density and thickness (the study Gupta's review counted as its one clinical study) |
| Ersan 2024 (PMID 39174804) | 30 men, prospective, no control group | Foreskin-derived stromal-cell exosomes injected into the scalp | Hair density up at weeks 4 and 12 (p < 0.05); no side effects observed |
| Wan 2025 (PMID 40146273) | 16 men, open-label, no control group | Microneedling followed by a topical exosome product | Average gain of 35 hairs per cm² at 12 months; mild tenderness and irritation resolving within 48 hours |
| Amini 2025 (PMID 40141845) | 20 men, randomized, placebo-controlled | Plant-extract exosome formulation vs saline, four sessions two weeks apart | Median hair-count gain 9.5 vs 1.5 at week 16 (p = 0.006); no notable adverse effects |
Only the last of these had a comparison group, and it is the smallest. It also tested an exosome preparation made with extracts of two plants, Ecklonia cava (a seaweed) and Thuja orientalis, rather than the human stem-cell exosomes most clinic marketing describes. The two open studies report real changes from baseline, but with no untreated group a reader cannot tell how much of the change the exosomes produced and how much came from the microneedling, the passage of time or the attention of being in a study. Ersan's paper grades itself as level IV evidence.
What the trial registry holds
ClinicalTrials.gov listed 19 studies of exosome treatments for hair loss on 28 September 2026. None had posted results. Eight were marked completed, among them a phase 2 comparison of exosomes with platelet-rich plasma (NCT06239207, 30 people) and a comparison of exosome injections with topical minoxidil (NCT07776015, 40 people). The largest registered study, a phase 2 trial of 120 men, was still recruiting (NCT07693244). One small early-phase study is listed as terminated (NCT06932393).
That is the gap worth watching. The comparison a reader wants, exosomes against the treatments with long records, has been run at least twice and not yet reported.
The benchmark: minoxidil and finasteride
For context, the same MEDLINE copy held 119 records tagged as randomized controlled trials that mention minoxidil and alopecia, against none tagged for exosomes. Minoxidil and finasteride are approved for pattern hair loss, and both have known side effects and limits. Exosomes may yet prove useful, but the evidence is at a different stage, and a treatment priced as an advance is being compared, in practice, with drugs that have decades of trials behind them. Our peptides for hair growth page applies the same benchmark to the peptide serums.
Safety, as reported
The open studies above report little beyond short-lived tenderness. Small studies cannot detect uncommon problems, and the wider record is less reassuring:
- The 2025 Queen and Avram review counted at least 10 serious adverse events reported after exosome use across dermatology, and concluded that the field needs "consistent manufacturing standards and regulatory oversight to ensure product safety".
- A 2023 report describes an allergic (anaphylactic) reaction after stem-cell exosome injections given for alopecia, with swelling of the forehead and enlarged lymph nodes behind the ears (Zhuang 2023, PMID 36210495).
Manufacturing is the open question. The studies above describe exosomes from at least five different sources, prepared in different ways. A result from one product says little about another sold under the same word.
How regulators treat exosome products
For exosome serums and creams sold for the face, a label census of 53 exosome skincare products shows that most declare no exosome ingredient at all.
We found no FDA approval for any exosome product for hair loss. FDA's drug-label database held four product listings naming exosomes as an ingredient on 28 September 2026, including placenta- and fat-derived stem-cell exosome solutions; none carried an approval application number, and under 21 CFR 207.77 a listing in that database "does not denote approval". FDA's website refused our requests on 28 September 2026, so this page does not quote the agency's own consumer notices on exosome and stem-cell products. Readers can find them on fda.gov by searching "exosome products".
What this supports saying
- Exosomes for hair are promising in the laboratory and unproven in the clinic: one 20-man placebo-controlled trial, of a plant-based product, and a handful of open studies.
- The comparison trials against minoxidil and PRP exist but have not reported.
- Exosome is a name for a kind of particle, not a product. Source and manufacturing vary, and results do not transfer between them.
- The most useful questions for anyone offered a treatment are what the product is made from, how it is regulated where it is being used, and what the clinician expects it to do that an approved treatment does not.
Exosomes also appear in facial "skin booster" treatments; our skin boosters page sets out how that category is sorted, and polynucleotides for skin covers the neighbouring DNA-based injectables.
Sources
- Queen D, Avram MR. Exosomes for Treating Hair Loss: A Review of Clinical Studies. Dermatol Surg 2025. PMID 39447204.
- Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration. J Cosmet Dermatol 2023. PMID 37381168.
- Amini F, et al. A Pilot Randomized Controlled Trial Evaluating the Efficacy of an Exosome-Containing Plant Extract Formulation for Treating Male Alopecia. Life 2025. PMID 40141845.
- Ersan M, et al. Effectiveness of Exosome Treatment in Androgenetic Alopecia. Aesthetic Plast Surg 2024. PMID 39174804.
- Wan J, et al. A Prospective Study of Exosome Therapy for Androgenetic Alopecia. Aesthetic Plast Surg 2025. PMID 40146273.
- Park BS, et al. Effects of exosome from adipose-derived stem cell on hair loss: a retrospective analysis of 39 patients. J Cosmet Dermatol 2022. PMID 35157363.
- Zhuang J, Chen Y, Hu J. Treatment of Anaphylaxis After Injection of Stem Cell Exosomes. J Craniofac Surg 2023. PMID 36210495.
- ClinicalTrials.gov, search: condition alopecia or hair loss, intervention exosome(s) or extracellular vesicles, read 28 September 2026.
- Europe PMC (MEDLINE subset), title and abstract searches, 28 September 2026.
- openFDA drug label API, search on product ingredients for "exosome"/"exosomes", 28 September 2026; 21 CFR 207.77.